Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621
Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309
Turtle, 2016, CD19 CAR-T cells are highly effective in ibrutinib-refractory chronic lymphocytic leukemia [abstract], Blood, 128, 10.1182/blood.V128.22.56.56
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222
Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025
Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415
Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226
Locke, 2017, Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma, Mol Ther, 25, 285, 10.1016/j.ymthe.2016.10.020
Hay, 2017, Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies, Drugs, 77, 237, 10.1007/s40265-017-0690-8
Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208
Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930
Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Fitzgerald, 2017, Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Crit Care Med, 45, e124, 10.1097/CCM.0000000000002053
Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751
Maude, 2014, Managing cytokine release syndrome associated with novel T cell-engaging therapies, Cancer J, 20, 119, 10.1097/PPO.0000000000000035
Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360
Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729
Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040
Valentijn, 2011, Functional architecture of Weibel-Palade bodies, Blood, 117, 5033, 10.1182/blood-2010-09-267492
Fiedler, 2004, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies, Blood, 103, 4150, 10.1182/blood-2003-10-3685
Metcalf, 2008, Formation and function of Weibel-Palade bodies, J Cell Sci, 121, 19, 10.1242/jcs.03494
Mikacenic, 2015, Biomarkers of endothelial activation are associated with poor outcome in critical illness, PLoS One, 10, e0141251, 10.1371/journal.pone.0141251
Page, 2013, Biomarkers of endothelial activation/dysfunction in infectious diseases, Virulence, 4, 507, 10.4161/viru.24530
Page, 2013, Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome, J Infect Dis, 208, 929, 10.1093/infdis/jit268
Page, 2011, Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome, Clin Infect Dis, 52, e157, 10.1093/cid/cir125
Ricciuto, 2011, Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis, Crit Care Med, 39, 702, 10.1097/CCM.0b013e318206d285
Lovegrove, 2009, Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children, PLoS One, 4, e4912, 10.1371/journal.pone.0004912
Darwish, 2013, Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction, Virulence, 4, 572, 10.4161/viru.25740